Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) has received a consensus recommendation of “Hold” from the seven research firms that are covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $7.43.
A number of equities analysts have issued reports on GRPH shares. BMO Capital Markets downgraded Graphite Bio from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $14.00 to $7.00 in a report on Friday, January 6th. Royal Bank of Canada decreased their price objective on Graphite Bio from $11.00 to $4.00 and set a “sector perform” rating for the company in a report on Friday, January 6th. SVB Leerink downgraded Graphite Bio from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $11.00 to $2.00 in a report on Friday, January 6th. Finally, Bank of America downgraded Graphite Bio from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $7.00 to $3.00 in a report on Wednesday.
Institutional Investors Weigh In On Graphite Bio
Institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP purchased a new stake in shares of Graphite Bio in the third quarter worth $34,000. Walleye Capital LLC purchased a new stake in shares of Graphite Bio during the first quarter valued at $57,000. Jane Street Group LLC purchased a new stake in shares of Graphite Bio during the third quarter valued at $37,000. ExodusPoint Capital Management LP purchased a new stake in shares of Graphite Bio during the third quarter valued at $41,000. Finally, American International Group Inc. boosted its position in shares of Graphite Bio by 69.7% during the first quarter. American International Group Inc. now owns 14,656 shares of the company’s stock valued at $75,000 after buying an additional 6,020 shares during the last quarter. 52.51% of the stock is owned by hedge funds and other institutional investors.
Graphite Bio Stock Down 0.5 %
Graphite Bio (NASDAQ:GRPH – Get Rating) last posted its quarterly earnings data on Wednesday, November 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.04. On average, research analysts anticipate that Graphite Bio will post -1.83 earnings per share for the current year.
About Graphite Bio
Graphite Bio, Inc, a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme.
- Get a free copy of the StockNews.com research report on Graphite Bio (GRPH)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Graphite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graphite Bio and related companies with MarketBeat.com's FREE daily email newsletter.